Evaluation of miR-122 as a Serum Biomarker for Hepatotoxicity in Investigative Rat Toxicology Studies

Veterinary Pathology

Volumn 53, Issue 1, 2016, Pages 211-221

  Sharapova, T ^a   Devanarayan, V ^a   LeRoy, B ^a   Liguori, M J ^a   Blomme, E ^a   Buck, W ^a   Maher, J ^a  

^a ABBVIE INC   (United States)

Author keywords

biomarker; drug induced liver injury; hepatotoxicity; histopathology; liver transaminases; microRNA; rat; serum; toxicology

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GLUTAMATE DEHYDROGENASE; MICRORNA; MIRN122 MICRORNA, RAT;

ANIMAL; BLOOD; DISEASE MODEL; EVALUATION STUDY; LIVER; MALE; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; TOXIC HEPATITIS; TOXICOLOGY;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DISEASE MODELS, ANIMAL; GLUTAMATE DEHYDROGENASE; LIVER; MALE; MICRORNAS; RATS; RATS, SPRAGUE-DAWLEY; TOXICOLOGY;

EID: 84951987566     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985815591076     Document Type: Article

References (43)

1. J.BraseD.WuttigR.Kuner. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 2010;9(1):306.
2. L.BreimanJ.H.FriedmanT.A.Olshen. Classification and Regression Trees. Belmont, CA: Wadsworth & Books1984.
3. D.CacchiarelliI.LegniniJ.Martone. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med. 2011;3(5):258–265.
4. H.H.ChengH.S.YiY.Kim. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One. 2013;8(6):e64795.
5. J.D.ClarkeT.SharapovaA.D.Lake. Circulating microRNA 122 in the methionine- and choline-deficient mouse model of non-alcoholic steatohepatitis. J Appl Toxicol. 2014;34(6):726–732.
6. P.DavorenR.McNeillA.Lowery. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol. 2008;9(1):76.
7. G.DeRosaR.W.Swick. Metabolic implications of the distribution of the alanine aminotransferase isoenzymes. J Biol Chem. 1975;250(20):7961–7967.
8. R.DuttaguptaR.JiangJ.Gollub. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One. 2011;6(6):e20769.
9. D.EnnulatM.Magid-SlavS.Rehm. Diagnostic performance of traditional hepatobiliary biomarkers of drug-induced liver injury in the rat. Toxicol Sci. 2010;116(2):397–412.
10. C.EsauS.DavisS.F.Murray. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2):87–98.
11. Food & Drug Administration. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Washington, DC: Food & Drug Administration; 2009.
12. B.GanterS.TugendreichC.I.Pearson. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol. 2005;119(3):219–244.
13. D.J.GrahamL.GreenJ.R.Senior. Troglitazone-induced liver failure: a case study. Am J Med. 2003;114(4):299–306.
14. S.M.HammondE.BernsteinD.Beach. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature. 2000;404(6775):293–296.
15. A.H.HarrillJ.RoachI.Fier. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther. 2012;92(2):214–220.
16. L.HeG.J.Hannon. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–531.
17. H.M.HeneghanN.MillerM.J.Kerin. Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol. 2010;28(29):e573–e574.
18. C.L.JoplingM.YiA.M.Lancaster. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science. 2005;309(5740):1577–1581.
19. N.Kaplowitz. Drug-induced liver injury. Clin Inf Dis. 2004;38(suppl 2):S44–S48.
20. X.Y.KongY.Q.DuL.Li. Plasma miR-216a as a potential marker of pancreatic injury in a rat model of acute pancreatitis. World J Gastroenterol. 2010;16(36):4599–4604.
21. N.KosakaH.IguchiT.Ochiya. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101(10):2087–2092.
22. J.KrutzfeldtN.RajewskyR.Braich. Silencing of microRNAs in vivo with “antagomirs.”Nature. 2005;438(7068):685–689.
23. M.Lagos-QuintanaR.RauhutA.Yalcin. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12(9):735–739.
24. O.F.LaterzaL.LimP.W.Garrett-Engele. Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem. 2009;55(11):1977–1983.
25. J.H.Lewis. “Hy’s law,” the “Rezulin Rule,” and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf. 2006;15(4):221–229.
26. K.J.LivakT.D.Schmittgen. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–408.
27. K.MurataH.YoshitomiS.Tanida. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2010;12(3): R86.
28. M.M.K.OngC.LatchoumycandaneU.A.Boelsterli. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci. 2007;97(1):205–213.
29. C.C.PritchardE.KrohB.Wood. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res. 2012;5(3):492–497.
30. J.B.RedellA.N.MooreN.H.Ward3rd. Human traumatic brain injury alters plasma microRNA levels. J Neurotrauma. 2010;27(12):2147–2156.
31. A.Reuben. Hy’s law. Hepatology. 2004;39(2):574–578.
32. X.RobinN.TurckA.Hainard. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
33. V.ScariaM.HariharanS.Maiti. Host-virus interaction: a new role for microRNAs. Retrovirology. 2006;3(1):68.
34. J.R.Senior. How can “Hy’s law” help the clinician?Pharmacoepidemiol Drug Saf. 2006;15(4):235–239.
35. J.SongZ.BaiW.Han. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci. 2012;57(4):897–904.
36. K.SongT.LiE.Owsley. A putative role of micro RNA in regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes. J Lipid Res. 2010;51(8):2223–2233.
37. R.Temple. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15(4):241–243.
38. H.D.VanGuilderK.E.VranaW.M.Freeman. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques. 2008;44(5):619–626.
39. K.WangS.ZhangB.Marzolf. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009;106(11):4402–4407.
40. P.B.WatkinsP.J.SeligmanJ.S.Pears. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008;48(5):1680–1689.
41. J.WittmannH.M.Jack. Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta. 2010;1806(2):200–207.
42. R.Z.YangS.ParkW.J.Reagan. Alanine aminotransferase isoenzymes: molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity. Hepatology. 2009;49(2):598–607.
43. Y.ZhangY.JiaR.Zheng. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem. 2010;56(12):1830–1838.